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ABSTRACT
Tramadol is used in both human and veteri-
nary medicine to treat postoperative pain. 
In human subjects, variation in metabolism 
of tramadol has led to inconsistent analge-
sia in some individuals. The purpose of the 
current study was to evaluate tramadol as a 
sole postoperative analgesic and to compare 
drug plasma concentration to clinical pain 
score. A high or low dose of tramadol was 
randomly assigned and administered to 14 
mixed breed female dogs after ovariohys-
terectomy. The Short-Form of the Glasgow 
Composite Measure Pain Scale was used 
for pain evaluation post-operatively. Plasma 
was collected for evaluation of tramadol and 
O-desmethyltramadol concentrations. The 
effect of weight and dose on pain scores as 
well as how pain score correlated with plas-
ma concentration of tramadol and O-des-
methyltramadol was evaluated. A significant 
difference in pain score was noted between 
doses when weight classes were pooled. The 
plasma concentrations did not correlate with 
pain score. Based on our results, the use of 
tramadol as a sole analgesic agent provides 
inadequate postoperative pain control but 
further evaluation of tramadol as a postop-
erative analgesic agent is needed.
INTRODUCTION
Pain management in the veterinary patient 
can be complicated and frustrating for both 
practitioners and owners. With patients that 
do not speak and hide their pain as an evo-
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lutionary trait it is difficult to determine the 
effective analgesic dose in any individual. 
Finding a medication that is easy to use, ef-
fective and safe can be challenging; espe-
cially when medicating dogs in the home 
environment.  Failure to control postopera-
tive pain can result in the development of 
chronic pain and complex pain syndromes 
which often manifest as behavioral changes. 
Aggression, fear, and self-mutilation are not 
uncommon sequelae that can damage the 
human animal bond and have a substantial 
influence on patient wellbeing and client 
satisfaction. (Coderre, 1986; Ward, 1994; 
Weisman-Orr, 2004)
Due to the strictly enforced legal 
requirement to appropriately store and docu-
ment the use of schedule 2 opioids and the 
questionable efficacy of oral opioid adminis-
tration in dogs, veterinarians have turned to 
tramadol for the treatment of postoperative 
pain. It is often used as an adjunct to other 
analgesics, but in some cases may be used 
alone. (KuKanich, et al 2013; Pascoe, et al 
2011) In the United States, tramadol is typi-
cally administered to dogs orally in the form 
of 50 mg sustained-release tablets every 
6-12 hours.  
Compared with other oral opioid 
preparations tramadol has fewer legislative 
requirements being classified as schedule IV 
by the DEA. It is inexpensive, easy for own-
ers to administer and has minimal effects on 
the kidneys or liver. (Kongara, et al 2008; 
Tolman, 1998) Current dose recommenda-
tions in Plumb’s Veterinary Drug Handbook 
are wide ranging being anywhere from 2-4 
mg/kg orally every 12 hours. While vet-
erinary studies to date have found doses in 
the range of to5-10 mg/kg orally every 4-6 
hours are necessary to observe analgesic 
effects. (KuKanich, et al 2004; KuKanich, 
et al 2011) Therefore choosing a clinically 
effective dose can be challenging and a dose 
range based on both plasma concentration 
and corresponding clinical signs of analgesia 
has yet to be determined.  
Tramadol is a synthetic codeine analog 
composed of a racemic mixture of two en-
antiomers which have effects at the μ-opioid 
receptor, the δ-opioid receptor, and weakly 
at the κ-opioid receptor. Tramadol also in-
hibits endogenous serotonin and norepineph-
rine uptake. (Valle et al., 2000; Oliva et al., 
2002) The majority of tramadol’s analgesic 
effect is derived from the major metabolite 
O-desmethyltramadol (M1). (Grond and 
Sablotzki, 2004; KuKanich, et al 2004; Ku-
Kanich, et al 2011) Therefore any alterations 
or variability in metabolism of tramadol 
could affect the drug’s efficacy. (KuKanich, 
et al 2011)  In human subjects mutations 
of the CYP2D6 gene, a P450 enzyme, are 
well recognized. These polymorphisms lead 
to individual variability in metabolism and 
clearance. (Grond and Sablotzki, 2004) In 
dogs, there have been reports of low plasma 
concentrations of the M1 metabolite after 
tramadol was administered via the oral and 
rectal routes. (Giorigi, et al 2009) Variabil-
ity in plasma concentration in dogs could 
be related to polymorphisms in expression 
of CYP450 genes as seen in humans and 
may explain some of the clinical variability 
observed with tramadol administration for 
analgesia in dogs.
Currently published studies investigating 
the efficacy and pharmacokinetics of trama-
dol have only evaluated the antinociceptive 
effects when the drug was administered prior 
to surgery or nociceptive testing. (Coderre, 
et al 1986; Mastrocinque and Fantoni 2003; 
KuKanich, et al 2004; KuKanich, et al 2011; 
Davila, et al 2013; Tiexeira, et al 2013). As 
most veterinary practitioners prescribe tra-
madol as an analgesic following surgery or 
to treat an animal already in pain it is diffi-
cult to extrapolate a clinically effective dose 
for canine patients based on the published 
literature. To the authors’ knowledge there 
have been no published studies in the dog 
evaluating the clinical analgesia provided by 
tramadol when administered post celiotomy 
as an oral tablet and correlating the clinical 
analgesia to plasma concentration of trama-
dol and its metabolites. 
The objectives of this study were to 
evaluate the efficacy of tramadol as a sole 
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postoperative analgesic agent by assess-
ing the clinical analgesic effects using the 
Glasgow Composite Measure Pain Scale 
(GCMPS-SF).  Further we intended to 
determine the correlation between these 
pain scores and the plasma concentrations of 
tramadol and O-desmethyltramadol. Finally, 
we analyzed the degree of variability in 
the plasma concentration of tramadol and 
O-desmethyltramadol amongst individu-
als within the same dose groups and at two 
different doses. Based on previous studies 
evaluating tramadol pharmacokinetics and 
clinical analgesia following orthopedic 
procedures (Benitez, et al 2015a; Benitez, et 
al 2015b) we hypothesized that individual 
and dose variability in plasma concentration 
of both tramadol and o-desmethyltramadol 
would be apparent in the clinical evaluation 
as assessed by a validated pain scoring sys-




Fourteen healthy client-owned female dogs 
that were pre-enrolled in the University Of 
Minnesota College Of Veterinary Medicine 
junior small animal surgery spay/neuter 
laboratory were recruited for evaluation. On 
admission to all dogs underwent a physical 
examination, blood was drawn and a mea-
surement for packed cell volume and total 
solids was obtained. Dogs were excluded 
from the study if they were under 6 months 
of age, if physical examination or history 
revealed any ongoing illness, or if they were 
currently receiving any analgesic medica-
tions. Dogs were hospitalized overnight 
prior to their surgical procedure. All study 
protocols were reviewed, approved, and 
conducted in accordance with the University 
of Minnesota Animal Care and Use Commit-
tee (IACUC number: 1311-31087A) Written 
informed consent was obtained from all dog 
owners prior to enrollment into the study.
Study Design
A prospective, blinded, randomized com-
plete block design, pilot study involving 
14 healthy female dogs (ASA status I or 
II) undergoing ovariohysterectomy under 
general anesthesia. Dogs were separated 
into two groups based on weight (<15 kg 
and >15 kg). There were 4 dogs less than 
15 kilograms enrolled and 10 dogs greater 
than 15 kilograms enrolled These groups 
were further subdivided to receive either 
a high dose of tramadol (10mg/kg PO) or 
a low dose (4 mg/kg PO) upon anesthetic 
recovery.a Tramadol was dosed within 
0.88 mg of the calculated dose based on a 
minimum tablet size containing 12.5 mg 
obtained from quartering tablets. Students 
were then provided with the tramadol in an 
envelope to be administered postoperatively. 
The evaluator (EGD) was unaware of the 
dose each dog received.
Anesthesia
A standardized anesthetic plan was used 
in all patients undergoing ovariohyster-
ectomy in the laboratory. Premedication 
with acepromazine at 0.02-0.04mg/kg and 
Morphine at 0.6-1 mg/kg was administered 
intramuscularly to allow for intravenous 
catheter placement using aseptic technique.  
After intravenous catheter placement, anes-
thesia was induced by administering propo-
fol intravenously to effect (loss of palpebral 
reflex, loose jaw-tone) with or without 
ketamine at 2 mg/kg intravenously. The 
trachea was intubated and anesthesia was 
maintained with isoflurane to effect in oxy-
gen. A balanced isotonic crystalloid solution 
(5-10 mL/kg/h, IV) was administered during 
surgery. Blood pressure was measured using 
a Doppler and sphygmomanometer, arterial 
hemoglobin saturation using pulse oximetry, 
heart rate via an esophageal stethoscope, and 
respiratory rate by direct observation, and 
intermittent end-tidal carbon dioxide con-
centration using capnometry were monitored 
during anesthesia. Anesthetic time was no 
less than 2 hours and no more than 6 hours 
from premedication to extubation for all 
dogs. 
Appropriate level of recovery from 
general anesthesia was based on the patient’s 
ability to swallow and right herself. Patients 
were then medicated with either the high or 
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low dose (as previously described) of oral 
tramadol based on previous random assign-
ment. The time of successful administration 
of the oral tramadol was the start time for 
evaluation.  Patients were hospitalized over-
night in a small animal ward. 
Pain Scoring
One blinded observer (EGD) evaluated dogs 
at 2, 4, 6, 8, and 12 hours post tramadol 
administration. Evaluation incorporated the 
Short Form of the Glasgow Composite Mea-
sure Pain Scale (GCMPS-SF). (Reid, et al 
2007) Any dog that scored greater than 6/24 
on GCMPS-SF was rescued with injection 
of meloxicam (0.1 mg/kg SQ) or carprofen 
(2.2 mg/kg SQ) and hydromorphone (0.1mg/
kg IM). The hydromorphone treatment 
was repeated at the same dose as deemed 
necessary (EGD). Once rescued, the dog 
was removed from further pain scoring and 
blood collection.
Plasma Collection and Evaluation
Peripheral venipuncture was performed at 
2, 4, 8, and 12 hours post tramadol admin-
istration in dogs greater than 15 kg. Veni-
puncture was performed after pain scores 
were obtained. Blood collection was not 
performed in the smaller dogs 
(<15 kg). Approximately 3 mL 
of whole blood was collected 
into EDTA tubes and was im-
mediately centrifuged at 3000 
rpm for 12 minutes. Plasma 
was pipetted into a screw top 
vial and labelled with time and 
patient I.D. All samples were 
stored in -30oC freezer until 
time of plasma evaluation. 
Samples were shipped over-
night to University of Tennes-
see Veterinary Pharmacology 
Laboratory. Plasma samples 
were evaluated using com-
mercially available reference 
standards. An LC-MS assay 
for tramadol and O-desmeth-
yltramadol (M1) was used to 
evaluate levels of drug at each 
time point. (Ceccato, et al 
2000; Patel, et al 2009) 
After the 12 hour evaluation, the study 
was completed and any dogs that had not 
received rescue analgesia during the study 
period were treated with meloxicam (0.1 
mg/kg SQ) or carprofen (2.2 mg/kg SQ). 
Hydromorphone (0.05 mg/kg IM) was ad-
ministered as needed. 
Statistical analysis
Explanatory values included, high dose ver-
sus low dose, weight class, and time while 
outcome variables included, plasma drug 
concentration (tramadol and O-desmethyl-
tramadol) and pain scale (GCMPS-SF). All 
data was input into a spreadsheet program 
then transferred to a statistical software 
package.c, d
The Shapiro-Wilks test was used to 
evaluate goodness of fit.  All outcome vari-
able data was entered as a mean. Bivariate 
analysis was used to compare outcome 
variables (pain score, drug plasma level) to 
the explanatory variable data (weight, dose).  
Student’s t-test was used to evaluate differ-
ence in pain score between doses and weight 
classes, and the difference in plasma concen-
tration of tramadol and O-desmethytramadol 
Figure 1, Pain Score for High and Low Dose: Average 
pain score on the GCMPS-SF for high (10 mg/kg PO) and 
low (4mg/kg PO) doses of tramadol for both weight groups. 
Time in hours is represented on the x-axis and pain score is 
represented on the y-axis. Patients with a pain score higher 
than 6 were removed from the study and provided rescue 
analgesia. (*) represent significant difference from first pain 
score Student’s t-test (p<0.05).
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between weight classes and doses.  
Significance was set at P<0.05
RESULTS
14 intact female dogs were en-
rolled in the study, one dog from 
the greater than 15 kg group was 
excluded from further evaluation 
after a dysphoric recovery. The pa-
tient was assumed to be painful and 
immediate analgesia and sedation 
was administered without formal 
pain scoring. Thirteen dogs received 
tramadol postoperatively and were 
pain scored. Data for these 13 dogs 
was analyzed. 
Pain Scoring
There was a significant difference 
in average pain score between the 
high dose and low dose groups at 
6 and 8 hours when weight classes 
were pooled. (Figure 1)  When pain 
scores were pooled, for both weight 
classes and drug doses, there was a 
significant reduction in pain score over time 
after the 6 hour time point. (Figure 2).
There was no significant difference in 
pain score between large and small dogs. 
Two dogs in the less than 15 kg group (n=4) 
required rescue analgesia, one from the 
high dose group and one from the low dose 
group. For the dogs in the greater than 15 
kg group (n=9), 4/9 of dogs in the high dose 
group required rescue analgesia and 2/4 
of the dogs in the low dose group required 
rescue analgesia. (Figure 3)
Plasma Drug Concentration
Plasma concentration of tramadol 
and O-desmethyltramadol for each 
dose group was plotted against time 
for dogs over 15 kg. Only dogs that 
were assessed to the 12 hour point are 
represented. Of the 8 dogs in which 
plasma concentrations were measured, 
all but one dog exhibited a peak level 
of tramadol at approximately 8 hours 
after oral dosing. Three of the 8 dogs 
required rescue analgesia prior to the 
12 hour evaluation. All three of these 
dogs were rescued after the 4 hour as-
sessment. Two of the rescued dogs had 
a tramadol plasma concentration that 
decreased from the 2 hour measure-
ment to the 4 hour measurement. One 
dog had an increase in the tramadol 
Figure 2, Pain Score for All Doses and All Weights: 
Pooled average pain score on the GCMPS-SF for all 
dogs. Time in hours is represented on the x-axis and 
pain score is represented on the y-axis. Patients with a 
pain score higher than 6 were removed from the study 
and provided rescue analgesia. (*) represent signifi-
cant difference from baseline using the Student’s t-test 
(p<0.05).
Figure 3, Pain Score Variation between Weight 
Classes: Average pain score at each time point for 
dogs less than 15 kg and dogs greater than 15 kg. 
Time in hours is represented on the x-axis and pain 
score is represented on the y-axis. Patients with a 
pain score higher than 6 were removed from the 
study and provided rescue analgesia.
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plasma concentration at the 4 hour 
measurement compared with the 2 
hour measurement. Further plasma 
concentration measurements or 
pain evaluations were not per-
formed in the three dogs requiring 
rescue analgesia. (Figure 4A and 
Figure 4B)
Plasma Drug Concentration and 
Pain Score
Average pain score for dogs over 
15 kg was plotted against tramadol 
and O-desmethyltramadol concen-
tration at 2, 4, 8, and 12 hours. A 
correlation between peak tramadol 
plasma concentration and increased 
pain score was noted, however, 
this was not significant. When pain 
score was compared with time, 
pain score consistently decreased 
over time from 4 hours after drug 
administration. There was also 
a positive association between 
decreasing plasma concentrations 
(for both tramadol and M1) and 
increasing time. (Figure 5A and 
Figure 5B)
DISCUSSION
Previously published data on the 
use of tramadol in dogs has shown 
that a dose of less than 9-10 mg/kg 
PO does not consistently provide 
adequate analgesia. (KuKanich, 
et al 2004, KuKanich, et al  2011) 
Based on our results it is possible 
that even the 10 mg/kg recom-
mended dose will not guarantee 
efficacy. We suspect that variability 
in metabolism between individuals 
is the cause for this general trend 
toward insufficient analgesia 
observed in our study. Human 
subjects exhibit polymorphisms 
of the CYP450 enzymes, these 
polymorphisms lead to individual 
variability in metabolism and clear-
ance. (Grond, et al 2004; Meyer, 
et al 2015)We suspect that similar 
polymorphism is seen in canine 
Figure 4, Plasma Concentration for Tramadol and O-
desmethyltramadol Over Time: (A) Tramadol concen-
trations for dogs over 15 kg. both high and low dose 
individuals are represented but only dogs that were not 
rescue and were evaluated for 12 hours are illustrated. 
Dog 1, dog 6, and dog 7 all required rescue analgesia 
prior to the 12 hour evaluation. Hours are represented 
on the x-axis and concentration in ng/mL as well as 
pain score is represented on the y-axis. (B) O-desmeth-
yltramadol (M1) concentrations for dogs over 15 kg. 
both high and low dose individuals are represented but 
only dogs that were not rescue and were evaluated for 
12 hours are illustrated. Dog 1, dog 6, and dog 7 all 
required rescue analgesia prior to the 12 hour evalua-
tion. Hours are represented on the x-axis and concen-
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subjects and accounts for the variability in 
plasma concentration observed in our study. 
Further investigation into the metabolism 
of tramadol, genetic mutations in metabolic 
enzymes, and how this variation within 
different breeds of dog affects tramadol ef-
ficacy is warranted.
Based on the data presented here, the 
currently recommended dosing interval 
of every 6-8 hours is inadequate. These 
findings are in agreement with 
previous studies which recom-
mend a shorter dosing interval 
of 4-6 hours. (KuKanich, et al 
2004, KuKanich, et al 2011) In 
our study, a peak in plasma con-
centration of tramadol and O-
desmethytramadol was observed 
at approximately 4 hours for 
most of the studied individuals. 
It is worth noting that the peak 
plasma concentration for trama-
dol and M1 noted at 4 hours did 
not correspond with decreasing 
pain score. Pain score was not 
significantly lower until the 
6 and 8 hours assessments in 
patients who received the high 
dose of tramadol. It is possible 
that alternative active metabo-
lites, that were not measured, 
are contributing to the analgesic 
effects or that the majority of 
the acute pain caused by the 
surgical procedure has subsided 
by 6-8 hours postoperatively. 
In addition to possible poly-
morphisms or alternative active 
metabolites this study also 
introduces the concept of non-
responders. In human subjects 
a small number of those treated 
with tramadol show no anal-
gesic effect even at high dose 
ranges. These patients have a 
mutation in the CYP2D6 gene 
can greatly affect the plasma 
concentration of O-desmethyl 
tramadol. (Stamer, et al 2003; 
Grond, et al 2004)  We believe 
that further investigation into 
breed variation in clinical analgesic response 
to tramadol would allow us to explain why 
some of the dogs in this study had markedly 
higher pain scores than other dogs despite 
similar procedures and identical dosing regi-
mens. The authors believe that repeating this 
study with a larger sample size would yield 
more significant results and may reveal more 
consistent trends in breed or size variation in 
(B)
(A)
Figure 5, Plasma Concentration for Tramadol and 
O-desmethyltramadol Over Time Compared with Pain 
Score Over Time: (A) Average plasma concentrations 
for dogs over 15 kg administered the low dose (4 mg/kg) 
at 4 time points post tramadol administration. Hours are 
represented on the x-axis and concentration in ng/dL as 
well as pain score is represented on the y-axis. dark bars 
represent tramadol plasma concentration and light bars 
represented O-desmethyltramadol (M1) plasma concentra-
tion. The line is the average pain score at each time point.  
(B) Average plasma concentrations for dogs over 15 kg 
administered the high dose (10 mg/kg) at 4 time points 
post tramadol administration. Hours are represented on 
the x-axis and concentration in ng/dL as well as pain 
score is represented on the y-axis. dark bars represent O-
desmethyltramadol (M1) plasma concentration and light 
bars represented tramadol plasma concentration. The line 
is the average pain score at each time point. 
Vol. 14, No.1, 2016 • Intern J Appl Res Vet Med.112
plasma concentration and response.
While many patients may have a higher 
pain score in the initial hours following sur-
gery and individual observation may vary, 
the Short Form of the Glasgow Composite 
Measure Pain Scale has been well validated 
for evaluation of postoperative pain in the 
canine patient and a rescue level of 6/24 is 
recognized as ethical and standard.(Reid, et 
al 2007) We feel confident that the pain scor-
ing in this study was accurate and represen-
tative of clinical analgesia.
Limitations to this study include the 
small sample size and potentially the marked 
differences in individual students’ surgical 
technique and tissue handling. It is expected 
that seasoned veterinary practitioners would 
have both better surgical skills and much 
shorter procedure duration. A non-treatment 
control group was not included in this study 
due to ethics. While the tramadol dose 
administered to each dog was within 0.88 
mg of the calculated dose, this variation 
may have led to some variability in plasma 
concentration and clinical analgesia.
While collection of data on more animal 
to evaluate the analgesia and pharmacoki-
netics of tramadol after ovariohysterectomy 
was considered, the very high rescue analge-
sia requirements in this pilot raised concerns 
about continuing. 
Although large statistical variation was 
not observed, due to small sample size, is 
important to recognize that this study has 
revealed clinically significant information. 
Thirty to fifty percent of dogs in both the 
high and low dose groups across weight 
classes required rescue analgesia. In as many 
as half of the dogs treated, oral tramadol was 
not adequate as a sole analgesic agent when 
administered post operatively.
In conclusion, tramadol was unable to 
consistently provide adequate analgesia to 
dogs following an abdominal surgery. The 
authors feel confident in recommending 
that tramadol should not be used as the sole 
postoperative analgesic in dogs following 
invasive surgical procedures.
FOOTNOTES
a.  Tramadol,  Amneal Pharmaceuticals, 
Bridgewater, NJ 
b.  LRS, Abbot Laboratories Chicago, IL
c.  Excel 2015. Microsoft. Redmond, WA
d.  GraphPad Prism. 2015. San Diego, CA
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